Business Description
Camurus AB
ISIN : SE0007692850
Compare
Compare
Traded in other countries / regions
CAMX.SwedenCAMRF.USACAMXs.UK7CA.Germany IPO Date
2016-01-05Description
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 48.55 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.04 | |||||
| Interest Coverage | 418.36 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 44.7 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 69.3 | |||||
| 3-Year Book Growth Rate | 19.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 36.21 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.51 | |||||
| 9-Day RSI | 37.76 | |||||
| 14-Day RSI | 42.04 | |||||
| 6-1 Month Momentum % | 56.9 | |||||
| 12-1 Month Momentum % | 124.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.41 | |||||
| Quick Ratio | 4.13 | |||||
| Cash Ratio | 3.23 | |||||
| Days Inventory | 309.41 | |||||
| Days Sales Outstanding | 53.71 | |||||
| Days Payable | 232.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | -0.11 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.87 | |||||
| Operating Margin % | 31.07 | |||||
| Net Margin % | 25.13 | |||||
| FCF Margin % | 34.05 | |||||
| ROE % | 33.61 | |||||
| ROA % | 26.38 | |||||
| ROIC % | 58.4 | |||||
| ROC (Joel Greenblatt) % | 579.63 | |||||
| ROCE % | 41.71 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 68.02 | |||||
| Forward PE Ratio | 105.26 | |||||
| PE Ratio without NRI | 68.02 | |||||
| Price-to-Owner-Earnings | 74.62 | |||||
| PS Ratio | 17.06 | |||||
| PB Ratio | 18.98 | |||||
| Price-to-Tangible-Book | 18.36 | |||||
| Price-to-Free-Cash-Flow | 49.09 | |||||
| Price-to-Operating-Cash-Flow | 48.27 | |||||
| EV-to-EBIT | 48.74 | |||||
| EV-to-Forward-EBIT | 79.31 | |||||
| EV-to-EBITDA | 47.53 | |||||
| EV-to-Forward-EBITDA | 76.61 | |||||
| EV-to-Revenue | 15.63 | |||||
| EV-to-Forward-Revenue | 13.08 | |||||
| EV-to-FCF | 47.25 | |||||
| Price-to-Projected-FCF | 281.47 | |||||
| Price-to-Graham-Number | 7.28 | |||||
| Price-to-Net-Current-Asset-Value | 22.34 | |||||
| Price-to-Net-Cash | 34.89 | |||||
| Earnings Yield (Greenblatt) % | 2.05 | |||||
| FCF Yield % | 2.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Camurus AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 149.056 | ||
| EPS (TTM) (€) | 0.643 | ||
| Beta | 0.83 | ||
| Volatility % | 50.98 | ||
| 14-Day RSI | 42.04 | ||
| 14-Day ATR (€) | 0.762642 | ||
| 20-Day SMA (€) | 43.993 | ||
| 12-1 Month Momentum % | 124.87 | ||
| 52-Week Range (€) | 19.05 - 51.95 | ||
| Shares Outstanding (Mil) | 57.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Camurus AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Camurus AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Camurus AB Frequently Asked Questions
What is Camurus AB(FRA:7CA)'s stock price today?
The current price of FRA:7CA is €42.22. The 52 week high of FRA:7CA is €51.95 and 52 week low is €19.05.
When is next earnings date of Camurus AB(FRA:7CA)?
The next earnings date of Camurus AB(FRA:7CA) is 2024-05-08.
Does Camurus AB(FRA:7CA) pay dividends? If so, how much?
Camurus AB(FRA:7CA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers